Recombinant Gastric Inhibitory Polypeptide (GIP) Homo sapiens (Human) Recombinant protein

Incretin hormone; Glucose Dependent Insulinotropic Peptide

Add to Cart Distributors
Overview
Properties
  • Source Prokaryotic expression, Host E.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationSecreted
  • Molecular Mass 18.6kDa, Accurate 19kDa(Analysis of differences refer to the manual)
  • Residues & TagsGlu22~Arg153 with N-terminal His Tag
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 90%
  • Isoelectric Point7.9
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Recombinant Gastric Inhibitory Polypeptide (GIP) Packages (Simulation)
  • Recombinant Gastric Inhibitory Polypeptide (GIP) Packages (Simulation)
  • Recombinant Gastric Inhibitory Polypeptide (GIP) Figure. Gene Sequencing (Extract)
  • RPA882Hu01.jpg SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Sequence

Usage

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • The anti-hyperglycemic efficacy of a lipid-lowering drug Daming capsule and the underlyingsignaling mechanisms in a rat model of diabetes mellitus.pubmed:27721485
  • The Effects of Duodenojejunal Omega Switch in Combination with High-Fat Diet and Control Diet on Incretins, Body Weight, and Glucose Tolerance in Sprague-Dawley Rats.pubmed:28840471
  • Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague …Pubmed:29098544
  • Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
  • Low AS160 and high SGK basal phosphorylation associates with impaired incretin profile and type 2 diabetes in adipose tissue of obese patientsPubmed: 31734225
  • The Leading Role of Peptide Tyrosine Tyrosine in Glycemic Control After Roux-en-Y Gastric Bypass in RatsPubmed: 31701411
  • Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetesPubmed:35251693

Recommend products